NasdaqHealth CareHealth Care FacilitiesS&P SmallCap 600
$37.00
+2.21 (+6.35%)
Close of Nov 06, 2026 · end-of-day data
ACHC 8-K filings in 2025
Every material Form 8-K Acadia Healthcare filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Acadia Healthcare reported third-quarter 2025 revenue of $851.6 million, up 4.4% year over year, but diluted earnings per share fell to $0.40 from $0.74 and adjusted EBITDA fell to $173.0 million from $194.3 million. The company lowered its full-year 2025 revenue, adjusted EBITDA and adjusted EPS guidance, and COO Dr. Nasser Khan resigned effective November 3, 2025.
Q3 revenue $851.6 million, up 4.4%; same-facility admissions up 3.3%
Net income attributable to Acadia $36.2 million, or $0.40 per diluted share, vs $0.74 a year earlier
Full-year adjusted EBITDA guidance cut to $650 million to $660 million from $675 million to $700 million
Dr. Nasser Khan resigned as COO effective November 3, 2025; receives a $515,000 lump-sum payment by March 15, 2026
Acadia Healthcare appointed Todd Young as Chief Financial Officer, effective October 27, 2025, replacing interim CFO Timothy Sides, who will return to his prior Senior Vice President, Operations Finance role. Young most recently served as CFO of Elanco Animal Health, and his employment agreement sets a $725,000 base salary and a target annual bonus of 85% of base salary beginning with 2026.
Todd Young becomes CFO effective October 27, 2025; Timothy Sides served as interim CFO and returns to Senior Vice President, Operations Finance.
Young was CFO of Elanco Animal Health from November 2018, and previously CFO of ACADIA Pharmaceuticals from August 2016 to October 2018.
Employment agreement includes a $725,000 base salary, a $460,000 one-time cash award, and $1,200,000 in one-time restricted stock units.
Severance eligibility applies on termination without Cause or resignation for Good Reason, including 12 months of base salary.
Acadia Healthcare reported second-quarter 2025 revenue of $869.2 million, up 9.2% from a year earlier, but net income attributable to the company fell to $30.1 million, or $0.33 per diluted share, from $78.5 million, or $0.85. The company also updated its 2025 guidance and said CFO Heather Dixon will step down effective August 15, 2025, with Senior Vice President Tim Sides named interim CFO effective August 16, 2025.
Q2 2025 revenue $869.2 million, up 9.2%; adjusted EPS $0.83 versus $0.91 in Q2 2024
Net income attributable to Acadia $30.1 million, or $0.33 per diluted share, versus $78.5 million, or $0.85, a year earlier
2025 guidance: revenue $3.3 billion to $3.35 billion; adjusted EPS $2.45 to $2.65; startup losses $60 million to $65 million, a $10 million increase
CFO Heather Dixon resigns effective August 15, 2025; Tim Sides becomes interim CFO effective August 16, 2025 at a $445,000 base salary
Acadia Healthcare reported first-quarter 2025 revenue of $770.5 million, up slightly from $768.1 million a year earlier, but net income attributable to the company fell to $8.4 million, or $0.09 per diluted share, from $76.4 million, or $0.83. The company affirmed its full-year 2025 guidance, which includes $2.50 to $2.80 in adjusted earnings per diluted share.
Revenue was $770.5 million versus $768.1 million in Q1 2024, a 0.3% increase.
Net income attributable to Acadia was $8.4 million ($0.09 per diluted share), down from $76.4 million ($0.83) a year earlier.
Adjusted EBITDA was $134.2 million versus $173.9 million, and transaction, legal and other costs were $31.1 million, including $31.0 million of government investigation costs.
Full-year 2025 guidance was affirmed, including revenue of $3.3 to $3.4 billion and adjusted EBITDA of $675 to $725 million.
Acadia Healthcare Company entered into an indenture dated March 10, 2025 for $550 million of 7.375% senior unsecured notes maturing March 15, 2033, sold in a private offering to qualified institutional and non-U.S. buyers. The company said it will use the proceeds to prepay outstanding borrowings under its senior secured revolving line of credit, which replaces floating-rate revolver debt with fixed-rate notes and adds $550 million of long-term debt to its balance sheet.
Notes total $550 million in principal, up $50 million from the $500 million launched March 5, 2025, and were offered at 100% of principal.
Interest of 7.375% per year is payable semi-annually on March 15 and September 15, starting September 15, 2025.
The company may redeem the notes on or after March 15, 2028, and may redeem up to 40% before then using equity offering proceeds at 107.375% of principal.
The indenture limits additional debt, liens, dividends, stock buybacks, asset sales and mergers, and the offering was expected to close March 10, 2025.
Acadia Healthcare entered a new credit agreement with JPMorgan Chase Bank as administrative agent, providing a $1 billion revolving facility and a $650 million term loan, both maturing February 28, 2030. The company used the proceeds to refinance obligations under its prior credit agreement, which it terminated, and the new facilities carry floating interest rates and financial covenants.
New $1 billion revolving facility and $650 million term loan, both maturing February 28, 2030
Proceeds used to refinance obligations under the Existing Credit Agreement, which was dated March 17, 2021 and scheduled to mature March 17, 2026
Borrowings bear floating rates: SOFR plus 1.375% to 2.250%, or base rate plus 0.375% to 1.250%, based on net leverage
Covenants include a Consolidated Total Net Leverage Ratio of no more than 5.0 to 1.0 and Interest Coverage of at least 3.0 to 1.0
Acadia Healthcare reported fourth-quarter 2024 revenue of $774.2 million, up 4.2% from a year earlier, but net income attributable to Acadia fell to $32.6 million, or $0.35 per diluted share, from $57.7 million, or $0.63, in the prior-year quarter. The company also issued 2025 guidance, including revenue of $3.3 to $3.4 billion and adjusted EPS of $2.50 to $2.80, and authorized a $300 million share repurchase program.
Q4 2024 revenue $774.2 million, up 4.2%; adjusted EBITDA $153.1 million versus $171.6 million a year earlier
Full-year 2024 revenue $3.15 billion, up 7.7%; net income attributable to Acadia $255.6 million versus a loss of $21.7 million in 2023
2025 guidance: revenue $3.3 to $3.4 billion, adjusted EBITDA $675 to $725 million, adjusted EPS $2.50 to $2.80
Board authorized share repurchases of up to $300 million with no expiration date; conference call scheduled February 28, 2025
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Acadia Healthcare filing is on SEC EDGAR ↗. 8-K briefs of other companies →